6920-24-7 Usage
Description
1,2-Hexadecanediol is a long-chain diol compound with the chemical formula C16H34O2. It is a colorless, odorless liquid at room temperature and has a molecular weight of approximately 258 g/mol. This organic compound is characterized by its two hydroxyl (-OH) groups attached to the first and second carbon atoms in a linear aliphatic chain of sixteen carbons.
Uses
Used in Nanotechnology:
1,2-Hexadecanediol is used as a reducing agent in the preparation of silver nanocrystals from a dichlorobenzene solution containing oleyl amine as a surfactant. Its reducing properties facilitate the formation of silver nanoparticles, which have various applications in electronics, medicine, and other fields.
Used in the Preparation of Au-Fe3O4 Hetero-dimers:
1,2-Hexadecanediol is utilized in the synthesis of Au-Fe3O4 hetero-dimers, which are hybrid nanoparticles combining gold and iron oxide. These hetero-dimers exhibit unique properties due to the combination of both materials, making them suitable for applications in catalysis, magnetic storage, and biomedical imaging.
Used in the Synthesis of Iron Pyrite Nanocrystals:
This diol compound is also employed in the preparation of monodisperse iron pyrite (FeS2) nanocrystals. Iron pyrite nanocrystals have potential applications in areas such as solar energy conversion, catalysis, and as components in electronic devices.
Used in the Production of Iron Platinum Nanoparticles:
1,2-Hexadecanediol plays a role in the synthesis of monodisperse iron platinum nanoparticles, which are of interest for their magnetic and catalytic properties. These nanoparticles can be used in various applications, including fuel cells, batteries, and as catalysts in the chemical industry.
Check Digit Verification of cas no
The CAS Registry Mumber 6920-24-7 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 6,9,2 and 0 respectively; the second part has 2 digits, 2 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 6920-24:
(6*6)+(5*9)+(4*2)+(3*0)+(2*2)+(1*4)=97
97 % 10 = 7
So 6920-24-7 is a valid CAS Registry Number.
InChI:InChI=1/C16H34O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-16(18)15-17/h16-18H,2-15H2,1H3
6920-24-7Relevant articles and documents
-
Weiss
, p. 1576 (1965)
-
Ring opening of a fatty epoxide by diethylacetamido malonate in basic medium by phase transfer catalysis or under microwave irradiation
Abenhaim,Loupy,Mahieu,Semeria
, p. 1809 - 1816 (1994)
A fatty epoxide (tetradecyl-oxirane) is reacted with diethyl acetamidomalonate in basic medium, with or without solvent under solid-liquid phase transfer catalysis with LiCl, or under microwave irradiation on supported reagents (KF/Al2O3/LiCl). The main product is a lactone which is formed after epoxide ring opening and subsequent cyclisation. We put here into evidence, for the first time, the conjugated advantages of 'dry media' reactions, lithium salt effects and microwave irradiation.
Total synthesis of (-)-goniotrionin
Dias, Luiz C.,Ferreira, Marco A. B.
experimental part, p. 4046 - 4062 (2012/06/29)
A stereoselective total synthesis of the reported structure of goniotrionin (4) has been accomplished. The key steps involved the opening of a chiral epoxide, a highly diastereoselective Mukaiyama aerobic oxidative cyclization, a selective 1,2-syn Mukaiyama aldol reaction, and a Noyori reduction.
DERMATOLOGICAL COMPOSITIONS AND METHODS
-
, (2008/06/13)
Disclosed are methods and compositions for regulating the melanin content of mammalian melanocytes; regulating pigmentation in mammalian skin, hair, wool or fur; treating or preventing various skin and proliferative disorders; by administration of various compounds, including alcohols, diols and/or triols and their analogues.
Treatment of diseases mediated by the nitric oxide/cGMP/protein kinase G pathway
-
, (2008/06/13)
Disclosed are methods and compositions for stimulating cellular nitric oxide (NO) synthesis, cyclic guanosine monophosphate levels (cGMP), and protein kinase G (PKG) activity for purposes of treating diseases mediated by deficiencies in the NO/cGMP/PKG signal transduction pathway, by administration of various compounds including alcohols, diols and/or triols and their analogues.
